Elisabetta Bonzano MD, PhD· @to_be_elizabeth · X·· 22 小时前评分70
正文 · 原文
📌 Proffered paper 2: Breast cancer, early and advanced stage
Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembro vs placebo plus chemotherapy in pts with HR+/HER2- advanced breast cancer
✨@hoperugo
#ESMO26 🇪🇸 @OncoAlert #OncoAlertAF
55 浏览 · 4 赞 · 3 转发 · 0 回复
会议摘要
LBA51按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)
https://esmocongress.esmo.org来源：Elisabetta Bonzano MD, PhD · x.com